Histamine induces chemotaxis and phagocytosis in murine bone marrow-derived macrophages and RAW 264.7 macrophage-like cells via histamine H 4-receptor

Inflammation Research

Volumn 63, Issue 3, 2014, Pages 239-247

  Czerner, Christoph P ^a   Klos, Andreas ^a   Seifert, Roland ^a   Neumann, Detlef ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bone marrow macrophage; Chemotaxis; Histamine; phagocytosis; RAW 264.7

Indexed keywords

ANIMALS; BONE MARROW CELLS; CELL LINE; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HISTAMINE; MACROPHAGES; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE;

EID: 84894440480     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0694-0     Document Type: Article

References (59)

1. + T cells. J Immunol. 2006;176:7062-70.
2. 1 receptors in scratching induced by histamine receptor agonists in BALB/c mice. Br J Pharmacol. 2004;142:374-80.
3. 4 receptor in allergic conjunctivitis in mice. Eur J Pharmacol. 2009;608:71-5.
4. 4 receptor antagonist on allergic rhinitis in mice. Int Immunopharmacol. 2009;9:734-8.
5. 4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007;119:176-83.
6. Beermann S, Glage S, Jonigk D, Seifert R, Neumann D. Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation. PLoS ONE. 2012;7:e30285.
7. 4 receptors modulate dendritic cell migration through skin-immunomodulatory role of histamine. Allergy. 2008;63:1387-94.
8. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003;305:1212-21.
9. 4-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:125-35.
10. 4R species variants. Mol Pharmacol. 2010;77:734-43.
11. 4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004;309:404-13.
12. 4 receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation. Eur J Immunol. 2011;41:1764-73.
13. 2-receptors. Int Immunopharmacol. 2001;1:1867-76.
14. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-69.
15. Kennedy MN, Mullen GED, Leifer CA, Lee C, Mazzoni A, Dileepan KN, Segal DM. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem. 2004;279:34698-704.
16. Godowski PJ. A smooth operator for LPS responses. Nat Immunol. 2005;6:544-6.
17. Suzuki E, Ninomiya Y, Umezawa K. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-κB inhibitor (-)-DHMEQ. Biochem Biophys Res Commun. 2009;379:379-83.
18. 4 receptor reduces LPS-induced TNF production in vivo. Inflamm Res. 2013;62:599-607.
19. Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M, Monsma FJ Jr. Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther. 2004;296:1058-66.
20. Suresh A, Sodhi A, Singh SM, Basu S. In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C. Int J Immunopharmacol. 1991;13:189-95.
21. Sodhi A, Suresh A. Production of reactive nitrogen intermediates by bone marrow-derived macrophages on treatment with cisplatin in vitro. Clin Exp Immunol. 1992;89:502-8.
22. Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. 2008. doi: 10.1101/pdb.prot5080.
23. Sodhi A, Suresh A, Singh SM. In vitro activation of rGM-CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide. Immunol Cell Biol. 1991;69:235-41.
24. Sodhi A, Suresh A, Singh SM. Effect of interferon-gamma, tumor necrosis factor, interleukin-1 and interleukin-6 on the modulation of anti-tumor responses of bone marrow derived macrophages. Int J Immunopharmacol. 1993;15:327-34.
25. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-73.
26. + T cells in an indirect manner. J Interferon Cytokine Res. 2012;32:185-90.
27. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-64.
28. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80:1298-307.
29. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-55.
30. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol. 2001;167:2991-9.
31. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-98.
32. Shi X. Resident macrophages in the cochlear blood-labyrinth barrier and their renewal via migration of bone-marrow-derived cells. Cell Tissue Res. 2010;342:21-30.
33. Tamagawa E, Bai N, Morimoto K, Gray C, Mui T, Yatera K, Zhang X, Xing L, Li Y, Laher I, Sin DD, Man SFP, van Eeden SF. Particulate matter exposure induces persistent lung inflammation and endothelial dysfunction. Am J Physiol Lung Cell Mol Physiol. 2008;295:L79-85.
34. Longbrake EE, Lai W, Ankeny DP, Popovich PG. Characterization and modeling of monocyte-derived macrophages after spinal cord injury. J Neurochem. 2007;102:1083-94.
35. Berggreen E, Haug SR, Mkonyi LE, Bletsa A. Characterization of the dental lymphatic system and identification of cells immunopositive to specific lymphatic markers. Eur J Oral Sci. 2009;117:34-42.
36. Arko-Mensah J, Rahman MJ, Dégano IR, Chuquimia OD, Fotio AL, Garcia I, Fernández C. Resistance to mycobacterial infection: a pattern of early immune responses leads to a better control of pulmonary infection in C57BL/6 compared with BALB/c mice. Vaccine. 2009;27:7418-27.
37. Eske K, Breitbach K, Köhler J, Wongprompitak P, Steinmetz I. Generation of murine bone marrow derived macrophages in a standardised serum-free cell culture system. J Immunol Methods. 2009;342:13-9.
38. + macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunol. 2012;13:6.
39. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-11.
40. 1 receptor. J Allergy Clin Immunol. 2007;119:472-81.
41. 1 during differentiation of monocytes into macrophages. FEBS Lett. 2000;473:345-8.
42. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci. 2011;32:242-9.
43. 3 receptor as a drug discovery target. J Med Chem. 2011;54:26-53.
44. Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA. Immune regulation by histamine. Curr Opin Immunol. 2002;14:735-40.
45. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy. 2006;91:174-87.
46. Cho E-J, An H-J, Shin J-S, Choi H-E, Ko J, Cho Y-W, Kim H-M, Choi J-H, Lee K-T. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011;112:3648-59.
47. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 2003;4:117.
48. 4 receptor agonists. Bioorg Med Chem Lett. 2010;20:7191-9.
49. Seifert R, Strasser A, Schneider EH, Neumann D, Dove S, Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci. 2013;34:33-58.
50. Strasser A, Wittmann H-J, Buschauer A, Schneider EH, Seifert R. Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs. Trends Pharmacol Sci. 2013;34:13-32.
51. 4 receptor agonist. J Pharmacol Exp Ther. 2005;314:1310-21.
52. 4 receptor agonist VUF 8430. Br J Pharmacol. 2009;157:34-43.
53. 4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004;142:161-71.
54. 4 receptor: modulation of cell migration and function. Allergy. 2010;65:840-9.
55. 4-receptor: evidence for ligand-specific receptor conformations. Biochem Pharmacol. 2012;84:192-203.
56. 4 histamine receptor in human natural killer cells, monocytes, and dendritic cells. J Immunol. 2007;179:7907-15.
57. + T cells and inhibits allergic asthma in a murine model. J Immunol. 2007;178:8081-9.
58. Ferreira R, Santos T, Gonçalves J, Baltazar G, Ferreira L, Agasse F, Bernardino L. Histamine modulates microglia function. J Neuroinflamm. 2012;9:90.
59. 4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol. 2005;174:5224-32.